Edition:
United States

Regulus Therapeutics Inc (RGLS.O)

RGLS.O on Consolidated Issue listed on NASDAQ Capital Market

1.26USD
12 Jul 2019
Change (% chg)

-- (--)
Prev Close
$1.26
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
185,980
52-wk High
$4.07
52-wk Low
$0.80

Latest Key Developments (Source: Significant Developments)

Regulus Therapeutics Files For Resale Of Up To 27.8 Mln Shares Of Common Stock By The Selling Stockholders - SEC Filing
Wednesday, 5 Jun 2019 04:01pm EDT 

June 5 (Reuters) - Regulus Therapeutics Inc ::REGULUS THERAPEUTICS INC FILES FOR RESALE OF UP TO 27.8 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING.  Full Article

Regulus Announces Preliminary Results Of Planned Interim Data Analysis Of RGLS4326 In New Mouse Chronic Toxicity Study
Friday, 4 Jan 2019 04:05pm EST 

Jan 4 (Reuters) - Regulus Therapeutics Inc ::REGULUS ANNOUNCES PRELIMINARY RESULTS OF PLANNED INTERIM DATA ANALYSIS OF RGLS4326 IN NEW MOUSE CHRONIC TOXICITY STUDY.REGULUS THERAPEUTICS INC - NO ADVERSE OR OTHER SIGNIFICANT FINDINGS TO DATE ACROSS ALL DOSE GROUPS TESTED.REGULUS THERAPEUTICS INC - DATA PACKAGE TO BE SUBMITTED TO FDA TO SUPPORT POTENTIAL RESUMPTION OF PHASE 1 CLINICAL STUDY.REGULUS THERAPEUTICS INC - ANTICIPATES ENGAGEMENT WITH FDA IN COMING WEEKS TO DISCUSS RESOLUTION OF VOLUNTARY PAUSE IN HUMAN DOSING.  Full Article

Regulus Therapeutics Q3 Loss Per Share $1.18
Thursday, 8 Nov 2018 04:05pm EST 

Regulus Therapeutics Inc ::REGULUS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND RECENT UPDATES.Q3 REVENUE $100,000.Q3 LOSS PER SHARE $1.18.Q3 REVENUE VIEW $4,500 -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $-1.25 -- THOMSON REUTERS I/B/E/S.  Full Article

Regulus Announces Successful Restructuring Of Sanofi Collaboration
Tuesday, 6 Nov 2018 07:30am EST 

Nov 6 (Reuters) - Regulus Therapeutics Inc ::REGULUS ANNOUNCES SUCCESSFUL RESTRUCTURING OF SANOFI COLLABORATION.REGULUS THERAPEUTICS INC - REGULUS IS ELIGIBLE TO RECEIVE APPROXIMATELY $7 MILLION IN UPFRONT AND MATERIAL TRANSFER PAYMENTS..REGULUS THERAPEUTICS - UNDER TERMS OF AMENDMENT, CO IS ELIGIBLE TO RECEIVE ABOUT $7 MILLION IN UPFRONT AND MATERIAL TRANSFER PAYMENTS.REGULUS THERAPEUTICS INC - SANOFI WILL ASSUME DEVELOPMENT OF RG-012 FOR ALPORT SYNDROME.REGULUS THERAPEUTICS INC - REGULUS IS ALSO ELIGIBLE TO RECEIVE UP TO $40 MILLION IN DEVELOPMENT MILESTONE PAYMENTS.REGULUS THERAPEUTICS - SANOFI WILL REIMBURSE CO FOR CERTAIN OUT-OF-POCKET TRANSITION ACTIVITIES & ASSUME CO'S UPSTREAM LICENSE ROYALTY OBLIGATIONS.REGULUS - SANOFI TO ASSUME ALL FUTURE COSTS AND DEVELOPMENT ACTIVITIES ASSOCIATED WITH ADVANCEMENT OF RG-012, CURRENTLY IN PHASE 2 FOR ALPORT SYNDROME.  Full Article

Regulus Therapeutics Q2 Loss Per Share $0.13
Thursday, 9 Aug 2018 04:05pm EDT 

Regulus Therapeutics Inc ::REGULUS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND RECENT UPDATES.Q2 LOSS PER SHARE $0.13.Q2 EARNINGS PER SHARE VIEW $-0.16 -- THOMSON REUTERS I/B/E/S.CORPORATE RESTRUCTURING AND PIPELINE FOCUS EXPECTED TO EXTEND CASH RUNWAY.  Full Article

Regulus Therapeutics Says Workforce Reduction Of About 60 Pct Is Being Implemented
Thursday, 5 Jul 2018 05:00pm EDT 

July 5 (Reuters) - Regulus Therapeutics Inc ::REGULUS ANNOUNCES STRATEGIC UPDATE AND CORPORATE RESTRUCTURING.REGULUS ANNOUNCES STRATEGIC UPDATE AND CORPORATE RESTRUCTURING.EFFORTS AIMED AT EXTENDING CASH RUNWAY TO MID-2019.WORKFORCE REDUCTION OF APPROXIMATELY 60% IS BEING IMPLEMENTED.RECRUITMENT ACTIVITIES FOR RG-012 CLINICAL PROGRAM IN ALPORT SYNDROME HAVE BEEN PAUSED.ACTIONS ANTICIPATED TO YIELD OVER $20 MILLION OF ANNUALIZED SAVINGS, WHICH ARE INTENDED TO EXTEND CO'S CASH RUNWAY INTO MID-2019.DISCUSSIONS WITH SANOFI TO POTENTIALLY RESTRUCTURE PARTNERSHIP ARE ONGOING.RGLS4326 HAS BEEN GENERALLY SAFE AND WELL-TOLERATED IN PHASE 1 SINGLE ASCENDING DOSE (SAD) AND MAD STUDIES TO DATE.REGULUS THERAPEUTICS - VOLUNTARILY PAUSED PHASE 1 MULTIPLE ASCENDING DOSE STUDY FOR RGLS4326 DUE TO UNEXPECTED OBSERVATIONS IN 27-WEEK MOUSE CHRONIC TOXICITY STUDY.REGULUS- INITIATED INVESTIGATIVE STUDIES, PLANNING NEW 27-WEEK MOUSE CHRONIC TOXICITY STUDY WITH SOME CHANGES BELIEVED TO ADDRESS UNEXPECTED FINDINGS.REGULUS - IN NEAR-TERM, WILL CONCENTRATE EFFORTS ON INVESTIGATING UNEXPECTED MOUSE TOXICITY FINDINGS IN RGLS4326 PROGRAM, ADVANCING HBV PROGRAMS.  Full Article

Regulus Qtrly Net Loss Per Share $0.14
Wednesday, 7 Mar 2018 04:10pm EST 

March 7 (Reuters) - Regulus Therapeutics Inc ::REGULUS REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PIPELINE UPDATE.REGULUS THERAPEUTICS INC - QTRLY NET LOSS PER SHARE $0.14.  Full Article

Regulus Therapeutics Q3 loss per share $0.18
Tuesday, 7 Nov 2017 07:16pm EST 

Nov 7 (Reuters) - Regulus Therapeutics Inc ::Regulus reports third quarter 2017 financial results and recent events.Q3 revenue was less than $100,000.Q3 loss per share $0.18.Q3 revenue view $864,000 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.  Full Article

Regulus Q3 loss per share $0.18
Tuesday, 7 Nov 2017 04:10pm EST 

Nov 7 (Reuters) - Regulus Therapeutics Inc ::Regulus reports third quarter 2017 financial results and recent events.Q3 revenue $100,000.Q3 loss per share $0.18.Q3 revenue view $864,000 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.  Full Article

Regulus Therapeutics Q2 loss per share $0.41
Tuesday, 1 Aug 2017 04:10pm EDT 

Aug 1 (Reuters) - Regulus Therapeutics Inc :Regulus reports second quarter 2017 financial results and recent events.Q2 revenue $100,000.Q2 revenue view $873,000 -- Thomson Reuters I/B/E/S.Q2 loss per share $0.41.Q2 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S.  Full Article